The Antioxidant Effects of Capparis Ovata and Deferasirox in Patients with Thalassemia MajorHandan Duman1, Duran Canatan1*, Güchan Alanoglu2, Recep Sutçu3 and Tufan Nayır4
- *Corresponding Author:
- Duran Canatan
Department of Pediatric Hematology
Suleyman Demirel University, Turkey
E-mail: [email protected]
Received date: June 07, 2013; Accepted date: June 27, 2013; Published date: June 30, 2013
Citation: Duman H, Canatan D, Alanoglu G, Sutçu R, Nayir T (2013) The Antioxidant Effects of Capparis Ovata and Deferasirox in Patients with Thalassemia Major. J Blood Disord Transfus 4:142.doi: 10.4172/2155-9864.1000142
Copyright: © Duman H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Iron overload and auto-oxidation of unpaired globin chains is the main cause of oxidative stress in thalassemia. We aimed to show the additive antioxidant effect of capparis Ovata and deferasirox in thalassemic patients. A total number of 40 thalassemia major patient aged between 7-30 years, who have been taken regular red cell 15 cc/kg/month to maintain Hb >10 gr/dl) and chelation (30 mg/kg/day ICL-670) for one year are involved. They were divided into two groups as control and study group randomly. Both study and control groups were followed by regular transfusion and chelation therapy. In addition study group has been taken capparis marmalade at the breakfast with a dose of a dessert-spoon (12.5 gr) younger than 10 years and a soup-spoon (25 gr) older than 10 years for 6 months. Hematological and biochemical parameters, ferritin at every month and oxidative-antioxidant status (MDA, CAT, Gpx, SOD) were measured at the beginning and at the end of the study. Serum ferritin and MDA levels declined significiantly in both groups (for ferritin; control group p=0.00; study group p=0.00) during the study but a much more decrease occured at MDA levels in the capparis given group (p=0.02). There was no statistically significant difference between the groups at the initial and last SOD CAT, GPX, SOD levels. Further more in the study group a significant decrease in liver function tests has been occured (AST p= 0.05, ALT p= 0.01). The high levels of MDA in iron overloaded thalassemic patients is the best marker of oxidative stres. Generally decreased iron burden was associated with decreased oxidant damage. In vitro it was shown that iron chelators such as deferoxamine and deferipron neutrolyse intraselluler free iron and inhibits oxidation. Our findings suggest that combination of capparis with deferasirox maybe have additive effect on decreasing the oxidative damage and hepatoxicity.